GEDEON RICHTER

Board of Directors' dividend proposal to the 2025 Annual General Meeting

Budapest, 7 April 2025 - The Board of Directors proposes to the Annual General Meeting of 2025 the declaration and the payment of a total of HUF 93,000 million in dividends. Dividend payable to holders of common shares of the parent company is constituting 38.6% of the consolidated after-tax profit of the 2024 business year after positive adjustments related to impairment loss and negative adjustments related to unrealized financial gains and representing an effective payout rate of 38.8% of the consolidated after-tax profit. The proposal implies a per share dividend of (rounded) HUF 509, i.e. five-hundred-nine Hungarian Forints.

The exact dividend per share will be defined before the reference date of the ownership identification connecting to the payment of dividends based on the then prevailing number of shares outstanding (i.e. excluding treasury shares).

About Gedeon Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

For further information:

Investors:	Róbert Réthy, CFA	+36 20 342 2555
Media:	Zsuzsa Beke	+36 20 916 4507